Literature DB >> 32995665

Anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule.

Manal Alzaabi1, Abdel Hakim Taguri1, Ahmed Elbarky1,2.   

Abstract

PURPOSE: To describe a case of spontaneous anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule. OBSERVATION: A 60-year old woman with proliferative diabetic retinopathy underwent uneventful pars plana vitrectomy and phacoemulsification with posterior chamber intraocular lens (PCIOL) implants in both eyes. She developed diabetic macular edema (DME) in her right eye which failed to respond to repeated intravitreal injections of Aflibercept 2mg/0.05ml (Eylea®). The patient received an intravitreal Iluvien® implant to treat the recalcitrant DME after she showed a favorable temporary response to dexamethasone intravitreal implant (Ozurdex™).Six months later she presented with pain in the right eye due to elevated intraocular pressure (IOP). The Iluvien® implant was found to be dislodged into the anterior chamber (AC) in the presence of an intact posterior capsule and stable PCIOL implant. The migrated Iluvien implant was removed and IOP was controlled with a glaucoma drainage valve as it failed to respond to maximum anti-glaucoma medication. CONCLUSIONS AND IMPORTANCE: Intravitreal Iluvien® implant could migrate into the AC in a previously vitrectomized eyes in the presence of an intact posterior capsule.
© 2020 Published by Elsevier Inc.

Entities:  

Keywords:  Diabetic macular edema; Iluvien® implant

Year:  2020        PMID: 32995665      PMCID: PMC7501052          DOI: 10.1016/j.ajoc.2020.100922

Source DB:  PubMed          Journal:  Am J Ophthalmol Case Rep        ISSN: 2451-9936


  10 in total

1.  Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.

Authors:  Katja Hatz; Andreas Ebneter; Cengiz Tuerksever; Christian Pruente; Martin Zinkernagel
Journal:  Ophthalmologica       Date:  2018-02-02       Impact factor: 3.250

2.  OBSERVATION: FLUOCINOLONE ACETONIDE (ILUVIEN) IMPLANT MIGRATION INTO THE ANTERIOR CHAMBER.

Authors:  Vasileios T Papastavrou; Hadi Zambarakji; Ian Dooley; Haralabos Eleftheriadis; Timothy L Jackson
Journal:  Retin Cases Brief Rep       Date:  2017 Winter

Review 3.  Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

4.  Management of anterior chamber dislocation of dexamethasone implant.

Authors:  Sarita A Kishore; Shlomit Schaal
Journal:  Ocul Immunol Inflamm       Date:  2013       Impact factor: 3.070

5.  Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies.

Authors:  Rahul N Khurana; Suri N Appa; Colin A McCannel; Michael J Elman; Susan E Wittenberg; David J Parks; Saad Ahmad; Steven Yeh
Journal:  Ophthalmology       Date:  2013-07-24       Impact factor: 12.079

6.  Vitrectomy as a Risk Factor for Complicated Cataract Surgery.

Authors:  Moss J Fenberg; Kenneth J Hainsworth; Frank G Rieger; Dean P Hainsworth
Journal:  Mo Med       Date:  2016 Jan-Feb

7.  A Novel Technique for Repositioning of a Migrated ILUVIEN(®) (Fluocinolone Acetonide) Implant into the Anterior Chamber.

Authors:  Ibraheem A El-Ghrably; Ahmed Saad; Christiana Dinah
Journal:  Ophthalmol Ther       Date:  2015-07-22

8.  Scleral fixation of fluocinolone acetonide implant.

Authors:  Homayoun Tabandeh; Kourous Rezaei
Journal:  Am J Ophthalmol Case Rep       Date:  2020-06-12

Review 9.  Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.

Authors:  Horace Massa; Anindyt M Nagar; Athanasios Vergados; Panagiotis Dadoukis; Sudeshna Patra; Georgios D Panos
Journal:  J Int Med Res       Date:  2018-12-16       Impact factor: 1.671

Review 10.  Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review.

Authors:  William Fusi-Rubiano; Rebecca R Blow; Mark Lane; Rupal Morjaria; Alastair K Denniston
Journal:  Ophthalmol Ther       Date:  2018-09-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.